Novel Agents in the Treatment of Metastatic Colorectal Cancer
Authors:
- Stephen LeongSLStephen Leong
- Wells A. MessersmithWMWells A. Messersmith
- Aik Choon TanATAik Choon Tan
- S. Gail EckhardtSES. Gail Eckhardt
- 1 May 2010
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 16 (3) , 273-282
Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.Keywords
This publication has 129 references indexed in Scilit:
- Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinomaCancer Chemotherapy and Pharmacology, 2009
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitorsInternational Journal of Cancer, 2009
- Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis2009
- Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILNature Medicine, 2007
- HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 2007
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- Mutations of the BRAF gene in human cancerNature, 2002
- Apoptosis by Death FactorCell, 1997